Partial operations give Samsung Biologics fresh GMP biomanufacturing capacity of 60,000 liters. Total capacity of the plant will reach 240,000 liters once fully open in the first half of next year.
Swift growth
Samsung Biologics facilities are located close to Incheon International airport. Operations at Plant 1 begun in 2015, followed by two additional plants with Plant 3 opening in 2018.
Following the same swift growth schedule, it has taken the Korean CDMO just 23 months from the start of construction to get the first operations online at ‘super plant’ Plant 4. “Samsung is able to construct its plants quickly by implementing our unique parallel & 3D modeling processing, along with years of know-how built through construction of clean-room like facilities in semiconductor plants,” the South Korea CDMO told us.
Plant 4 is expected to help Samsung Biologics maximize operational efficiency in addition to further enhancing its scale up development and manufacturing capability in response to growing biopharmaceutical demand.
“At the P4 groundbreaking ceremony in late 2020, we committed to have the plant up and running by October this year. I am very proud to have delivered on that promise, and confident that this will further solidify our position as a global leading CDMO,” said John Rim, CEO and President of Samsung Biologics.
Samsung Biologics says it has already sealed a number of large-scale manufacturing contracts with Plant 4: although would only clarify that the operations now running at the plant are ‘contract manufacturing services for a client product’.